NextCure Inc is a biotechnology business based in the US. NextCure shares (NXTC) are listed on the NASDAQ and all prices are listed in US Dollars. NextCure employs 90 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $5.13 |
|---|---|
| 52-week range | $4.95 - $14.40 |
| 50-day moving average | $5.90 |
| 200-day moving average | $7.38 |
| Wall St. target price | $17.14 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.46 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.13 from 2022-01-26
| 1 week (2022-01-21) | -4.29% |
|---|---|
| 1 month (2021-12-27) | -16.18% |
| 3 months (2021-10-28) | -38.12% |
| 6 months (2021-07-28) | -28.95% |
| 1 year (2021-01-28) | -57.88% |
|---|---|
| 2 years (2020-01-27) | -88.50% |
| 3 years (2019-01-24) | N/A |
| 5 years (2017-01-24) | N/A |
| Gross profit TTM | $-24,176,000 |
|---|---|
| Return on assets TTM | -15.23% |
| Return on equity TTM | -24.45% |
| Profit margin | 0% |
| Book value | $8.99 |
| Market capitalisation | $139.8 million |
TTM: trailing 12 months
We're not expecting NextCure to pay a dividend over the next 12 months.
Over the last 12 months, NextCure's shares have ranged in value from as little as $4.95 up to $14.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NextCure's is -0.1369. This would suggest that NextCure's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, NextCure has bucked the trend.
NextCure, Inc. , a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University.
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.